{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006994","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.114790+00:00","generated_at":"2026-05-16T11:14:13.722695+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028","bullets":["First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).","Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).","Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).","Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).","Cash, cash equivalents, and marketable securities expected to fund operations into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006994","json":"https://secwatch.observer/filing/0001193125-26-006994.json","markdown":"https://secwatch.observer/filing/0001193125-26-006994.md","text":"https://secwatch.observer/filing/0001193125-26-006994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/0001193125-26-006994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/d92848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:13.722695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}